Low-dose aspirin no benefit in prostate cancer
Low-dose aspirin does not increase survival in prostate cancer, according to a large Danish cohort study.
The study, published in Annals of Internal Medicine, followed 29 136 patients (median age, 70 years) with a diagnosis of prostate cancer for between five and seven years.
7633 died of prostate cancer and 5575 died of other causes during a median follow-up of 4.9 years. Post diagnosis low-dose aspirin use was associated with adjusted hazard ratios (HR) of 0.95 (95% CI, 0.89–1.01) for prostate cancer-specific mortality and 1.12 (CI, 1.05–1.20) for other-cause mortality. A secondary analysis showed that prostate cancer mortality was slightly reduced with low-dose aspirin use after five years (HR, 0.91 [CI, 0.83–1.01]) and 7.5 years (HR, 0.84 [CI, 0.72–0.97]).
According to the authors, although their study does not show any survival benefit from low-dose aspirin in the short-term, longer exposure periods might be associated with reduced prostate cancer mortality.